BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35911422)

  • 1. Past, present and future in low-risk myelodysplastic syndrome.
    Toprak SK
    Front Med (Lausanne); 2022; 9():967900. PubMed ID: 35911422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic strategies in low and high-risk MDS: What does the future have to offer?
    Scalzulli E; Pepe S; Colafigli G; Breccia M
    Blood Rev; 2021 Jan; 45():100689. PubMed ID: 32253020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
    van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
    Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
    Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
    J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
    Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
    Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems.
    Bektaş Ö; Üner A; Eliaçık E; Uz B; Işık A; Etgül S; Bozkurt S; Haznedaroğlu İC; Göker H; Sayınalp N; Aksu S; Demiroğlu H; Özcebe Oİ; Büyükaşık Y
    Turk J Haematol; 2016 Jun; 33(2):119-26. PubMed ID: 26376664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database.
    Enrico A; Bestach Y; Flores MG; Arbelbide J; Serale C; Novoa V; Crisp R; Rivas MM; Larripa I; Belli C
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):743-752.e5. PubMed ID: 28797621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
    Montalban-Bravo G; Garcia-Manero G
    Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
    Wang XQ;
    Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS).
    Kasprzak A; Nachtkamp K; Gattermann N; Germing U
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
    Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
    Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does mutational burden add to other prognostic factors in MDS?
    Nazha A
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101098. PubMed ID: 31779975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
    van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
    Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelodysplastic syndromes: diagnosis and staging.
    Malcovati L; Nimer SD
    Cancer Control; 2008 Oct; 15 Suppl():4-13. PubMed ID: 18813205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic Syndromes: A New Decade.
    Volpe VO; Garcia-Manero G; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):1-16. PubMed ID: 34544674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.
    de Swart L; Smith A; Johnston TW; Haase D; Droste J; Fenaux P; Symeonidis A; Sanz G; Hellström-Lindberg E; Cermák J; Germing U; Stauder R; Georgescu O; MacKenzie M; Malcovati L; Holm MS; Almeida AM; Mądry K; Slama B; Guerci-Bresler A; Sanhes L; Beyne-Rauzy O; Luño E; Bowen D; de Witte T
    Br J Haematol; 2015 Aug; 170(3):372-83. PubMed ID: 25907546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
    Garcia-Manero G; Chien KS; Montalban-Bravo G
    Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations.
    Polprasert C; Niparuck P; Rattanathammethee T; Chuncharunee S; Kobbuaklee S; Songserm K; Suksusut A; Trithiphen S; Lanamtieng T; Kongkiatkamon S; Chanswangphuwana C; Lawasut P; Bunworasate U; Rojnuckarin P
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e293-e299. PubMed ID: 34840089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.